

# Gabriele Pecher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7553764/publications.pdf>

Version: 2024-02-01

18  
papers

1,112  
citations

759233

12  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. <i>Molecular Therapy</i> , 2017, 25, 1248-1258.	8.2	305
2	MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines. <i>Immunological Reviews</i> , 1995, 145, 61-89.	6.0	250
3	The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2010, 46, 2926-2935.	2.8	149
4	Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 669-673.	4.2	144
5	Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology. <i>Frontiers in Immunology</i> , 2020, 11, 611163.	4.8	53
6	Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. <i>Leukemia Research</i> , 2005, 29, 301-306.	0.8	43
7	Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. <i>Cancer Gene Therapy</i> , 2002, 9, 390-398.	4.6	36
8	Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. <i>Virology</i> , 2006, 354, 252-260.	2.4	27
9	Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck. <i>Molecular and Clinical Oncology</i> , 2017, 7, 151-157.	1.0	22
10	Oral administration of a soluble $\alpha$ 3, $\beta$ 6-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice. <i>International Immunopharmacology</i> , 2009, 9, 1298-1303.	3.8	18
11	Cellular and Humoral Immunogenicity of Hamster Polyomavirus-Derived Virus-Like Particles Harboring a Mucin 1 Cytotoxic T-Cell Epitope. <i>Viral Immunology</i> , 2008, 21, 12-26.	1.3	16
12	Expression of mucin (MUC-1) from a Mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells. <i>Journal of Gene Medicine</i> , 1999, 1, 84-92.	2.8	15
13	Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 549-556.	4.2	11
14	Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2008, 56, 141-145.	2.3	7
15	Pattern of the Epitope-Specific IgG/IgM Response against Human Cytomegalovirus in Patients with Multiple Myeloma. <i>Vaccine Journal</i> , 2013, 20, 1298-1304.	3.1	6
16	Generation of an Immortalized Human CD4+ T Cell Clone Inhibiting Tumor Growth in Mice. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 738-742.	2.1	5
17	HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2. <i>Viruses</i> , 2021, 13, 83.	3.3	4
18	Expression of mucin (MUC-1) from a Mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells. <i>Journal of Gene Medicine</i> , 1999, 1, 84-92.	2.8	1